Better Health for All

Tharimmune's entire product pipeline is dedicated to developing therapeutic candidates for unmet medical needs, including treatments for chronic pruritus in primary biliary cholangitis (PBC), autoimmune diseases, and cancer, as well as prophylaxis for opioid overdose.

Phase 1 clinical trials for TH104 reported only mild adverse events, with no serious adverse events, and a comparable safety profile to intravenous nalmefene. The company's products target vulnerable populations such as PBC patients (an orphan disease affecting 178,000 in the US, with 75% experiencing pruritus) and high-risk individuals like military personnel and first responders exposed to potent opioids. However, the company's forward-looking statements are subject to risks detailed in SEC filings, and the dual focus on biotech and blockchain presents regulatory and investor challenges. Tharimmune raised approximately $13 million in the last 12 months for clinical trials and secured over $540 million in private placements, indicating investment in innovation. The development of TH104 for opioid overdose prophylaxis addresses a significant public health crisis. The company's operations are not explicitly linked to negative health externalities, but the article mentions the opioid crisis as a context for TH104's development. Clinical trials are conducted under GCP regulations, requiring informed consent and IRB review, with a Phase 1 study involving 20 healthy volunteers.

Fair Money & Economic Opportunity

Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates.

The provided articles detail its financial offerings, regulatory filings, and product development, but do not contain any information related to financial services, lending practices, customer demographics, or community finance initiatives. As such, the company does not offer lending or deposit services to consumers, nor does it provide consumer credit products or manage customer finance data. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to Tharimmune's core business or reported activities.

Fair Pay & Worker Respect

No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. While executive compensation figures are mentioned (e.g., CEO total compensation of $791.16K in 2025),

there is no data on median employee compensation, which is necessary to calculate the CEO to median pay ratio. Information regarding living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce is not available. The articles primarily focus on executive compensation, financial performance, and Nasdaq compliance issues, which do not provide the necessary metrics for this assessment.

Honest & Fair Business

No specific, concrete data points were found in the provided articles to assess Tharimmune, Inc. against any of the 'Honest & Fair Business' KPIs. Information regarding regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict percentages, anti-corruption policies, or third-party verification of ethical claims was not available.

While a Nasdaq non-compliance notice was issued for failing to meet stockholders' equity requirements, this was not identified as an ethics-related regulatory fine. Additionally, a statement of 'no known material legal proceedings' was present, but it did not provide specific details on ethics-related fines or their value.

No War, No Weapons

Tharimmune, Inc. is developing TH104, a potential prophylactic treatment for opioid exposure, explicitly targeting both military personnel and first responders.

The company has appointed James Gordon Liddy, a retired US Navy SEAL with a background in counterterrorism and national security, as a strategic advisor. The Department of Defense is noted to be procuring similar opioid prophylaxis countermeasures, indicating a market for such products for military use. This suggests that the company's R&D investment is split between civilian and military applications for this dual-use technology.

Safe & Smart Tech

Tharimmune's privacy policy, last revised in June 2023, allows users to opt out of marketing emails and control cookies via browser settings, which represents industry-standard user privacy controls.

The company's Board of Directors oversees management's processes for identifying and mitigating cybersecurity risks and is apprised of incidents with moderate or higher business impact. Tharimmune engages third-party services to conduct evaluations of security controls through penetration testing and independent audits. The company has a vulnerability disclosure program with a good scope and reasonable response times of 7-15 days. It also conducts regular security testing for 40-55% of its systems, with a comprehensive methodology for critical systems. Tharimmune must comply with regulations, including FDA requirements for safeguarding patient information and SEC reporting for cybersecurity incidents, and states it shares information to comply with the law.